CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics (CTMX) reported Long-Term Deferred Tax of $87.6 million for Q4 2018.

CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018) Analysis & Trends

CytomX Therapeutics has reported Long-Term Deferred Tax for 1 years, with the latest figure at $87.6 million in Q4 2018.

For the quarter ending Q4 2018, Long-Term Deferred Tax changed N/A year-over-year to $87.6 million; the trailing twelve-month figure through Dec 2018 stood at $87.6 million (changed N/A YoY), and the FY2018 full-year result was $87.6 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2018 stood at $87.6 million.
The five-year high for Long-Term Deferred Tax was $87.6 million in Q4 2018, with the low at $87.6 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	CytomX Therapeutics	520.30 Mn	173.59 Mn	-

Download Data

Date	Value
Dec 31, 2018	87.60 Mn